The first half of 2017 saw a substantial increase in national drug exports.
Ulisse Information System data show a 14% growth of 14% of Italian drug exports in the first six months of 2017 compared with the same period of 2016, with a flow of exports in the first six months of the year amounted to 10.7 billion euros.
The focus remains on quality: pharmaceutical raw materials produced in Italy are a sector of excellence in the drug chain. The industry has made exports in the premium price its main competitive factor and its plus compared to the competition. Over the past 10 years Italian exports of high-price Medicines rose by 5 billion euros.
The strength lies in the vanguard and bet on innovation. In recent years the Italian pharmaceutical industry has grown a lot from the perspective of research and development and on the frontier of innovation, increasing investments by 20% over the past 3 years in this area.
Research in Italy is increasingly specialized in biotechnology and biomedical fields, including digitization among factors to increase the quality of pathology management and the development of new care models that are revolutionizing the health industry in our Country.